Market Overview

HC Wainwright Slashes La Jolla Pharma Price Target, Estimates On Below-Expectation Guidance

Share:
HC Wainwright Slashes La Jolla Pharma Price Target, Estimates On Below-Expectation Guidance

La Jolla Pharmaceutical Company (NASDAQ: LJPC) reported net 2018 sales of $10.1 million for the septic shock treatment Giapreza this week and announced 2019 sales guidance of $24 million to $28 million for the drug. 

The guidance represents continued linear growth, despite the company’s plans efforts to reach an inflection point in Giapreza’s sales by moving to centralized contracting and offering volume discounts, according to H.C. Wainwright.

The Analyst

Analyst Edward White maintained a Buy rating on La Jolla and reduced the price target from $48 to $25.

The Thesis

La Jolla expects a decision in June on its Marketing Authorization Application to the European Medicines Agency for Giapreza, White said in a Wednesday note. 

If Giapreza receives EMA approval, it could be launched in Europe in the back half of 2019, according to La Jolla. 

The impact of the below-expectation Giapreza sales guidance for 2019 is offset partially by cost-cutting expectations in R&D and SG&A, the analyst said. 

H.C. Wainwright reduced its revenue estimates for the company from $17.5 million to $10 million in 2018 and from $89.7 million to $24.8 million in 2019. EPS estimates for 2018 were lowered from a $7.96 loss to an $8.16 loss and from a $6.03 loss to a $7.31 loss in 2019.

Price Action

La Jolla Pharmaceutical shares were rallying nearly 16 percent to $6.32 at the time of publication Wednesday. 

Related Links: 

The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase

Jefferies Downgrades La Jolla On Weak Forecast For Blood Pressure Drug 

Latest Ratings for LJPC

DateFirmActionFromTo
Jan 2019UpgradesUnderweightNeutral
Jan 2019UpgradesUnderperformHold
Aug 2018MaintainsUnderweightUnderweight

View More Analyst Ratings for LJPC
View the Latest Analyst Ratings

Posted-In: Analyst Color News Guidance Health Care Price Target Reiteration Analyst Ratings General Best of Benzinga

 

Related Articles (LJPC)

View Comments and Join the Discussion!
Need corporate guidance data?
Click here to see licensing options.

Latest Ratings

StockFirmActionPT
UDRBairdUpgrades
NKEBank of AmericaUpgrades
ARNCCowen & Co.Upgrades31.0
WDCLoop CapitalUpgrades
VARBTIGUpgrades130.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Pros Tackle Market Reaction, Democrats' Strategy After Trump's Oval Office Address

Sears Gets Temporary Reprieve: Lampert Has Hours To Raise $120 Million